SCHEMBL15539622

SCHEMBL15539622

Cc1ccccc1[C@@](C)(O)[C@H](O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
CASR P41180 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
HIF1A Q16665 1/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
HSP90AA1 P07900 1/20 0.33
MAPT P10636 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15538386 1.00 GABRA1 (0.36) GABRA1GABRB2CASRLMNAMAPK1
SCHEMBL16795793 1.00 GABRA1 (0.36) GABRA1GABRB2CASRLMNAMAPK1
SCHEMBL15540225 0.84 KCNN4 (0.44) LMNAMAPK1PDK1PDK2PDK3
SCHEMBL15539304 0.84 KCNN4 (0.44) LMNAMAPK1PDK1PDK2PDK3
SCHEMBL697581 0.81 CPT2 (0.35) CASRLMNAMAPK1HIF1AALDH1A1
SCHEMBL12817104 0.81 CPT2 (0.35) CASRLMNAMAPK1HIF1AALDH1A1
SCHEMBL15538966 0.81 KIF11 (0.41) LMNAMAPK1HIF1APDK1PDK2
SCHEMBL15539822 0.81 MAPT (0.36) LMNAMAPK1ALDH1A1HSP90AA1MAPT
SCHEMBL15539909 0.81 MAPT (0.36) LMNAMAPK1ALDH1A1HSP90AA1MAPT
SCHEMBL15540080 0.81 KIF11 (0.41) LMNAMAPK1HIF1APDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-02-13 US disclosed
EP-4211125-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-19 EP disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
WO-2022054987-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-03-17 WO disclosed
CN-106507667-B Sulfamate derivatives for the prevention or treatment of epilepsy 比皮艾思药物研发有限公司 2020-01-24 CN disclosed
EP-3443959-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2019-02-20 EP disclosed
EP-3079685-B1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO PHARM SOLUTIONS CO LTD (KR) 2018-11-28 EP disclosed
EP-3079686-B1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO PHARM SOLUTIONS CO LTD (KR) 2018-10-24 EP disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
EP-2861571-B1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO LTD (KR) 2017-05-03 EP disclosed
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-03 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
EP-3079685-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2016-10-19 EP disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
WO-2015088273-A9 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-08-06 WO disclosed
WO-2015088273-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed
EP-2861571-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME Bio-Pharm Solutions Co., Ltd. (KR) 2015-04-22 EP disclosed
WO-2013187727-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain SULT2A1, STS, SULT1A1 GABRA1 1272/4885GABRB2 1293/4885CASR 2118/4885
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 GABRA1 120/4885GABRB2 118/4885CASR 2908/4885
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME MYLK, MUSK, MYLK2 GABRA1 137/4885GABRB2 51/4885CASR 535/4885
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy STS, SULT2A1, GRIK5 GABRA1 196/4885GABRB2 90/4885CASR 2322/4885
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder SLC6A4, SLC6A3, SLC6A2 GABRA1 120/4885GABRB2 118/4885CASR 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.